eCTD Module 1: Regional Administrative Information and Requirements Guide
eCTD Module 1 contains all region-specific administrative information for a regulatory submission, including application forms, cover letters, patent and exclusivity information, and proposed labeling. Unlike Modules 2-5, which are harmonized globally under ICH M4, Module 1 is entirely region-specific. Each regulatory authority (FDA, EMA, Health Canada, PMDA, TGA) defines its own Module 1 structure and content requirements.
Key Takeaways
Key Takeaways
- Module 1 is the only non-harmonized CTD module — each regulatory authority (FDA, EMA, Health Canada) defines its own structure and content requirements.
- The most common Module 1 error causing submission delays is an outdated or incomplete application form (Form 356h for FDA, EU Application Form for EMA, HC/SC 3011 for Health Canada).
- FDA Module 1 requires patent information (Form 3542) for Orange Book listing, financial disclosure (21 CFR Part 54), and environmental assessment or categorical exclusion — none of which are required by EMA.
- EMA requires signed expert statements (quality, nonclinical, clinical) and PSMF/RMP/QPPV pharmacovigilance documentation in Module 1 — neither is required by FDA.
- eCTD Module 1 is the only module in the Common Technical Document that is not harmonized across ICH regions. It serves as the administrative and regulatory wrapper around the globally harmonized technical content in Modules 2-5. Every regulatory submission starts with Module 1, and its correct assembly is essential for avoiding Refuse to File decisions, gateway rejections, and administrative delays.
- Because Module 1 varies by region, regulatory professionals submitting to multiple authorities must prepare separate Module 1 packages for each target agency while reusing Modules 2-5. This regional variation is one of the primary sources of complexity in global regulatory submissions.
- In this guide, you will learn:
- The purpose and scope of eCTD Module 1 within the CTD framework
- FDA Module 1 requirements (US-specific administrative documents)
- EMA Module 1 requirements (EU-specific forms and labeling)
- Health Canada Module 1 differences
- Common Module 1 errors and how to avoid them
- ---
Module 1 in the eCTD Framework
Position Within the CTD Structure
The Common Technical Document (CTD) organizes regulatory submissions into five modules, as defined by ICH M4:
| Module | Content | Harmonized? |
|---|---|---|
| Module 1 | Regional administrative information | No (region-specific) |
| Module 2 | Quality, Nonclinical, Clinical Summaries | Yes (ICH M4) |
| Module 3 | Quality (CMC) data | Yes (ICH M4Q) |
| Module 4 | Nonclinical study reports | Yes (ICH M4S) |
| Module 5 | Clinical study reports | Yes (ICH M4E) |
Why Module 1 Is Not Harmonized
Module 1 contains documents that reflect each country's or region's unique regulatory, legal, and administrative requirements. These include:
- Application forms specific to each agency's regulatory process
- Patent and intellectual property provisions that differ by jurisdiction
- Labeling formats mandated by local law
- Environmental requirements unique to certain jurisdictions
- Fee payment documentation
- Legal representative and local agent information
ICH explicitly excluded Module 1 from harmonization because these administrative and legal requirements are determined by each nation's sovereignty, legal framework, and regulatory tradition.
FDA Module 1: United States Requirements
FDA defines its Module 1 requirements in the FDA eCTD Technical Conformance Guide and the FDA Regional Module 1 Specifications. The following sections describe the required and optional components.
FDA Module 1 Structure
| Section | Title | Content |
|---|---|---|
| 1.1 | Forms | FDA application forms |
| 1.2 | Cover Letter | Submission cover letter |
| 1.3 | Administrative Information | Patent, exclusivity, financial, other admin |
| 1.4 | References | Letters of authorization, references to DMFs |
| 1.5 | Application Status | Good standing certifications |
| 1.6 | Meetings | Meeting request documents, briefing materials |
| 1.7 | Fast Track | Fast Track designation request/grant |
| 1.8 | Special Protocol Assessment | SPA request and correspondence |
| 1.9 | Pediatric Information | Pediatric study plans, waivers, deferrals |
| 1.10 | Dispute Resolution | Formal dispute documentation |
| 1.11 | Information Amendment | Post-submission information |
| 1.12 | Other Correspondence | General correspondence with FDA |
| 1.13 | Annual Reports | IND/NDA annual reports |
| 1.14 | Labeling | Proposed prescribing information |
| 1.15 | REMS | Risk Evaluation and Mitigation Strategy |
| 1.16 | Promotional Material | Direct-to-consumer and professional materials |
| 1.17 | Risk Assessment | Environmental assessment or exclusion claim |
Section 1.1: FDA Forms
The forms required depend on the application type:
For NDA Submissions:
| Form | Title | Purpose |
|---|---|---|
| FDA Form 356h | Application to Market a New Drug, Biologic, or Antibiotic Drug | Cover form for NDA, sNDA, BLA, sBLA |
| FDA Form 1571 | Investigational New Drug Application | IND submissions (not for NDA) |
| FDA Form 3542 | Patent Information | Identifies patents covering drug, method of use, or formulation for Orange Book listing |
| FDA Form 3674 | Certification of Compliance (ClinicalTrials.gov) | Certifies clinical trial registration and results reporting under FDAAA Section 801 |
For BLA Submissions:
The same Form 356h is used, with BLA-specific fields completed. Additional facility information forms may be required.
Section 1.2: Cover Letter
The cover letter is a critical document that provides FDA reviewers with context for the submission. Required elements include:
| Element | Description |
|---|---|
| Application number | NDA/BLA number (or "New" for initial submissions) |
| Submission type | Original application, supplement, amendment |
| Drug name | Established name and proprietary name (if applicable) |
| Applicant information | Company name, address, contact |
| Description of submission | Purpose and contents of the eCTD sequence |
| Regulatory history | Reference to prior submissions, meetings |
| Cross-references | Authorization to reference other NDAs, DMFs, BLAs |
| Reviewer requests | Specific review considerations (e.g., expedited review request) |
Section 1.3: Administrative Information
1.3.1 Patent Information (Form 3542)
Under the Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984) and 21 CFR 314.53, NDA holders must submit patent information for listing in the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations). Required patent categories:
| Patent Type | What Is Listed |
|---|---|
| Drug substance (active ingredient) | Patents covering the active ingredient |
| Drug product (formulation/composition) | Patents covering the formulation |
| Method of use | Patents covering approved indications |
1.3.2 Patent Certification (for ANDAs/505(b)(2))
Under 21 CFR 314.94(a)(12), generic applicants must certify to each listed patent:
- Paragraph I: No patent listed
- Paragraph II: Patent has expired
- Paragraph III: Patent will expire (delay approval)
- Paragraph IV: Patent is invalid, unenforceable, or will not be infringed
1.3.3 Exclusivity
Sponsors may request market exclusivity under various provisions:
| Exclusivity Type | Duration | Legal Basis |
|---|---|---|
| New Chemical Entity (NCE) | 5 years | FD&C Act 505(c)(3)(E)(ii) |
| New Clinical Investigation | 3 years | FD&C Act 505(c)(3)(E)(iii) |
| Orphan Drug | 7 years | Orphan Drug Act (21 USC 360cc) |
| Pediatric | 6 months added | FD&C Act 505A |
| Qualified Infectious Disease Product (QIDP) | 5 years added | GAIN Act (FD&C Act 505E) |
1.3.4 Financial Certification/Disclosure
Under 21 CFR Part 54, sponsors must disclose financial interests of clinical investigators who participated in studies submitted in the application. This includes:
- Financial arrangements with sponsor
- Proprietary interest in the product
- Significant equity interest in the sponsor
- Payments exceeding $25,000
Section 1.14: Labeling
FDA Module 1 labeling includes:
| Document | Requirement |
|---|---|
| Prescribing Information (USPI) | Full prescribing information per 21 CFR 201.57 (Physician Labeling Rule format) |
| Highlights of Prescribing Information | Summary format per 21 CFR 201.57(a) |
| Patient labeling | Medication Guide (21 CFR 208) or Patient Package Insert |
| Annotated labeling | Draft label with annotations referencing supporting data in the NDA |
| Redline labeling | Track-changes version showing proposed changes (for supplements) |
| Structured Product Labeling (SPL) | XML-formatted label per FDA SPL Guidance |
| Container/carton labels | Package labels meeting 21 CFR 201 requirements |
Section 1.17: Environmental Assessment
Under the National Environmental Policy Act (NEPA) and 21 CFR 25, NDA applicants must either:
- Submit an Environmental Assessment (EA) evaluating environmental impact of manufacturing and use, or
- Claim a Categorical Exclusion under 21 CFR 25.31 (most drugs qualify)
EMA Module 1: European Union Requirements
EMA defines its Module 1 structure in the "Annex I to Directive 2001/83/EC" and the "Guidance on eCTD Submissions to the European Medicines Agency." EU Module 1 differs substantially from FDA Module 1 in structure and content.
EMA Module 1 Structure
| Section | Title | Content |
|---|---|---|
| 1.0 | Cover Letter | Submission cover letter |
| 1.1 | Comprehensive Table of Contents | Full submission TOC |
| 1.2 | Application Form | EU application form |
| 1.3 | Product Information | SmPC, PIL, labeling |
| 1.4 | Expert Reports | Quality, Nonclinical, Clinical expert statements |
| 1.5 | Specific Requirements | Conditional MA, exceptional circumstances |
| 1.6 | Environmental Risk Assessment | For veterinary and certain human medicinal products |
| 1.7 | Information on Orphan Designation | Orphan designation documentation |
| 1.8 | Information on Pharmacovigilance | PSMF, RMP summary |
| 1.9 | Information Relating to Clinical Trials | Paediatric Investigation Plan (PIP) |
Section 1.2: EU Application Form
The EU application form is a standardized document required for all centralized procedure (CP) applications to EMA. Key elements:
| Field | Content |
|---|---|
| Applicant details | Legal entity, contact information |
| Product details | INN, brand name, pharmaceutical form, strength |
| Legal basis | Article 8(3) (full application), Article 10 (generic/hybrid/biosimilar) |
| Therapeutic indication | Proposed wording |
| ATC code | Anatomical Therapeutic Chemical classification |
| Manufacturing sites | All manufacturing, testing, and batch release sites |
| Qualified Person (QP) | QP responsible for batch release in the EU |
Section 1.3: Product Information
EU Module 1 product information is fundamentally different from FDA labeling:
| Document | EU Requirement | FDA Equivalent |
|---|---|---|
| Summary of Product Characteristics (SmPC) | Standardized product information for healthcare professionals (Directive 2001/83/EC, Article 11) | Prescribing Information (USPI) |
| Patient Information Leaflet (PIL) | Patient-facing information (Article 59) | Medication Guide |
| Labeling text | Outer packaging, immediate packaging, blister labeling (Article 54-55) | Container/carton labels |
| Braille | Product name in Braille on outer packaging (Article 56a) | Not required |
The SmPC follows a fixed structure (QRD template) with numbered sections:
- Name of the medicinal product
- Qualitative and quantitative composition
- Pharmaceutical form
- Clinical particulars (indications, dosage, contraindications, warnings, interactions, fertility/pregnancy/lactation, effects on driving, adverse reactions, overdose)
- Pharmacological properties
- Pharmaceutical particulars
- Marketing authorisation holder
- Marketing authorisation number
- Date of first authorisation/renewal
- Date of revision of the text
- Dosimetry (radiopharmaceuticals)
- Instructions for handling (radiopharmaceuticals)
Section 1.4: Expert Reports/Statements
EU Module 1 requires signed expert statements (declarations) from:
- Quality expert (confirming Module 3 compliance with EU standards)
- Nonclinical expert (confirming Module 4 study compliance)
- Clinical expert (confirming Module 5 study compliance)
These expert statements are unique to the EU and have no direct FDA equivalent.
Section 1.8: Pharmacovigilance
EU Module 1 requires pharmacovigilance documentation not required in FDA Module 1:
| Document | Purpose |
|---|---|
| Pharmacovigilance System Master File (PSMF) summary | Demonstrates applicant's pharmacovigilance capability |
| Risk Management Plan (RMP) summary | Outlines risk identification, characterization, minimization |
| Qualified Person for Pharmacovigilance (QPPV) | Named individual responsible for EU PV |
Health Canada Module 1 Differences
Health Canada defines its Module 1 requirements in the "Guidance Document: Preparation of Drug Regulatory Activities in the CTD Format." Key differences from FDA and EMA:
Health Canada Module 1 Structure
| Section | Title | Notable Differences |
|---|---|---|
| 1.1 | Forms | HC-specific application forms |
| 1.2 | Cover Letter | Similar to FDA |
| 1.3 | Administrative Information | Drug Identification Number (DIN), data protection |
| 1.4 | Drug Establishment Licence | Required DEL documentation |
| 1.5 | Labeling | Canadian labeling (bilingual English/French requirement) |
| 1.6 | Risk Management/Risk Communication | RMP as per HC requirements |
| 1.7 | Product Monograph | Canadian Product Monograph (PM) |
Key Canada-Specific Requirements
| Requirement | Description |
|---|---|
| Bilingual labeling | All patient-facing labeling must be in English and French |
| Product Monograph (PM) | Canadian equivalent of SmPC/USPI; unique format per HC template |
| Drug Identification Number (DIN) | Unique identifier assigned by HC upon approval |
| Drug Establishment Licence (DEL) | Manufacturing site license under Canada's Food and Drug Regulations (C.01A.004) |
| Data Protection | 8 years of data protection + 6 months pediatric extension (C.08.004.1) |
| Priority Review (Canada) | Similar concept but separate process from FDA priority review |
Module 1 in Global Submissions
Managing Module 1 Across Multiple Regions
When preparing a global submission targeting multiple regulatory authorities, the strategy for Module 1 is:
| Component | Approach |
|---|---|
| Modules 2-5 | Same across all regions (harmonized per ICH M4) |
| Module 1 | Separate preparation for each region |
| Cover letter | Region-specific, referencing local application number |
| Forms | Region-specific forms required by each agency |
| Labeling | Region-specific format (USPI, SmPC, PM) |
| Patent/exclusivity | Jurisdiction-specific intellectual property strategy |
Module 1 Comparison: FDA vs EMA vs Health Canada
| Element | FDA | EMA | Health Canada |
|---|---|---|---|
| Application form | Form 356h | EU Application Form | HC New Drug Submission form |
| Main labeling doc | USPI (21 CFR 201.57) | SmPC (Directive 2001/83) | Product Monograph |
| Patient labeling | Medication Guide | PIL | Patient labeling (bilingual) |
| Expert statements | Not required | Required (quality, nonclinical, clinical) | Not required |
| Patent information | Form 3542 (Orange Book) | Not in Module 1 | C.08.004.1 data protection |
| Environmental | EA or categorical exclusion | ERA (Section 1.6) | Not standard |
| PV requirements | Not in Module 1 | PSMF, RMP, QPPV | RMP required |
| Financial disclosure | 21 CFR Part 54 | Not required | Not required |
| Language | English | English (for centralized procedure) | English and French |
Common Module 1 Errors and Prevention
Errors That Cause Gateway Rejections
| Error | Consequence | Prevention |
|---|---|---|
| Missing or incorrect FDA forms | ESG gateway rejection | Use current form versions from FDA website |
| Form fields not matching eCTD metadata | Validation failure | Cross-check form data against eCTD XML |
| Incorrect application number format | Routing failure | Verify format: NDA XXXXXX or BLA XXXXXX |
| Missing cover letter | Processing delay | Always include in Section 1.2 |
| SPL not compliant | Labeling processing failure | Validate SPL against FDA SPL schema |
Errors That Cause Refuse to File
| Error | Consequence | Prevention |
|---|---|---|
| Incomplete patent certification | RTF under 21 CFR 314.101 | Complete Form 3542 for all applicable patents |
| Missing financial disclosure | Integrity concern | Collect investigator financial information early |
| Labeling not compliant with PLR | Review delay | Follow 21 CFR 201.57 format exactly |
| Missing pediatric information | PREA violation | Address pediatric strategy per FDORA amendments |
| Environmental assessment absent | Cannot file | Submit EA or claim categorical exclusion |
Best Practices for Module 1 Assembly
- Start early: Module 1 preparation should begin 6-12 months before submission, particularly labeling negotiations and patent analysis
- Use current forms: Always download the latest version of FDA forms from fda.gov; outdated forms cause preventable rejections
- Cross-reference accurately: Module 1 documents must accurately reference content in Modules 2-5
- Validate before submission: Run eCTD validation tools to check Module 1 XML structure and document completeness
- Plan for region-specific timelines: EU expert statement requirements and Canadian bilingual labeling require additional lead time
- Track form revisions: FDA periodically updates forms; subscribe to FDA form update notifications
Module 1 is region-specific because it contains administrative, legal, and regulatory documents that reflect each country's unique regulatory framework. Patent laws, labeling requirements, application forms, and environmental regulations differ by jurisdiction. ICH recognized this during CTD development and intentionally excluded Module 1 from harmonization.
Key Regulatory References
| Reference | Citation |
|---|---|
| ICH M4: CTD Organization | ICH, "Organisation of the Common Technical Document," 2004 |
| ICH M8: eCTD Specification | ICH, "Electronic Common Technical Document," current version |
| FDA eCTD Technical Conformance Guide | FDA, current version |
| FDA Regional Module 1 Specifications | FDA, current version |
| NDA Content Requirements | 21 CFR 314.50 |
| BLA Content Requirements | 21 CFR 601.2 |
| Patent Information Submission | 21 CFR 314.53 |
| Financial Disclosure | 21 CFR Part 54 |
| Drug Labeling Requirements | 21 CFR 201.57 (Physician Labeling Rule) |
| Environmental Assessment | 21 CFR Part 25 |
| SPL Requirements | FDA Guidance, "Providing Regulatory Submissions in Electronic Format - SPL" |
| EU Directive on Medicinal Products | Directive 2001/83/EC |
| SmPC Guideline | QRD Template, EMA |
| Health Canada CTD Guidance | Health Canada, "Preparation of Drug Regulatory Activities in CTD Format" |
| Food and Drug Regulations (Canada) | C.08, C.01A |
| Hatch-Waxman Act | Drug Price Competition and Patent Term Restoration Act of 1984 |
| Pediatric Research Equity Act (PREA) | FD&C Act Section 505B |